Tampa, United States
Brian Levy is a clinical stage company founded in 2005 and headquartered in the United States. The company focuses on developing an orally administered compound to inhibit the dysregulated NLRP3 Inflammasome pathway of autoinflammation.
Their Phase 2 asset, Xiflam, is set to undergo clinical trials in 2022 for indications including Diabetic Macular Edema (DME) secondary to Diabetic Retinopathy (DR), Chronic Kidney Disease secondary to Diabetic Nephropathy (DN), and the Intermediate form of Age-Related Macular Degeneration (AMD).
The company employs InflammX technology with the objective of disease modification through inhibiting the dysregulated NLRP3 Inflammasome by normalizing pathological prematurely open hemichannels in the cell membrane.
The latest investment for Brian Levy was a $9.13M Venture Round investment on 12 January 2021.
Peer-reviewed literature on the inflammasome supports the Cx43 mechanism as an activator of the NLRP3 inflammasome, and drugs such as Xiflam have shown effectiveness in multiple disease states.
Brian Levy presents a promising opportunity in the Biotechnology, Health Care, and Pharmaceutical industries, with potential to address significant unmet medical needs through its innovative approach to modulating inflammasome-mediated autoinflammation.
